As discussed earlier, compounds with low solubility
sometimes might end-up providing inaccurate in
vitro biological data.
·
For example, insufficient solubility can
lead to inconsistencies between bioassay, underestimated activity, toxicity,
reduced hit rates and inaccurate structure activity relationship.
·
Poor solubility can limit the absorption
of compounds from the gastrointestinal tract which in turn reduces oral
bioavailability.
·
Therefore, poor solubility can influence
both pharmacokinetic and pharmacodynamic properties of the compound.
Therefore, solubility measurement is of utmost
importance in drug discovery programs.
MEASUREMENT OF SOLUBILITY:
During
ADME profiling we come across two types of solubility data. They are KINETIC
SOLUBILITY data & THERMODYNAMIC SOLUBILITY data.
What do they mean and how do we measure these!
These two terms are related to TIME. We do understand that KINETICS is
time-dependent event and THERMODYNAMICS is time independent phenomenon.
KINETIC
SOLUBILITY measurement is done something like this,
1. In
general stock solutions of desired compounds are prepared in DMSO (at a particular
concentration depending on the final concentration in the assay).
2. The
above compound DMSO solution is then diluted in the buffer of interest and
dispensed in microtiter plate. [When compound as DMSO solution is added to
aqueous buffer – precipitation of the compound occurs – and this precipitation
ofo the compound is measured at a range of concentrations]
3. These
plates are incubated at a particular temperature and time while shaking.
4. After
the above process, microplate’s content is filtered under vacuum and
collected.
5. The
concentration of compound in the filtrate is quantified by spectrophotometer.
THERMODYNAMIC
SOLUBILITY investigates the solubility of a
compound as a saturated solution in equilibrium. This measured solubility is dependent on the
pH of the solution at the equilibrium and the pKa of the compound.
Measurement
is done something like this,
1. Aqueous
solvent is added to solid compound. Here
excess solid should be used and relatively long mixing times are performed to
ensure equilibrium is achieved (16-72 hours – this is the incubation time)
2. After
this time, the saturated solution is filtered and quantified against a DMSO
stock solution using spectrophotometer.
___________
Since the majority of known drugs contain ionizable groups, the aqueous
solubility is assessed over a range of pH values. The compound is dissolved in buffer solutions
at the indicated pH values. The compound is allowed to reach thermodynamic
equilibrium by incubating for 18 hours. Compound UV absorption is
compared to fully saturated solution in 1-propanol.
Solubility report is given in mM units
___________
WHAT DID WE LEARN? WHICH SOLUBILITY
MEASUREMENT IS SUPERIOR!
Ø When we perform in vitro discovery screens (activity testing) –
compounds pre-dissolved in DMSO are used.
Therefore, kinetic solubility measurement (which is performed by using
DMSO stocks) is preferred method at the early stage discovery programs. [kinetic solubility assay conditions mimic many early in vitro
discovery screens – in that compounds are pre-dissolved in DMSO]
Ø While determining Kinetic solubility – we are basically
measuring precipitation rate rather than solubility. Therefore, a stock solution of compound of
interest in DMSO is gradually added to aqueous solvent (buffer solution) until
the anti-solvent properties of the water drive the compound out of the
solution.
Ø Not surprisingly, thermodynamic solubility is less useful in
early drug discovery. This becomes
important in late discovery and early development stages. During these stages we must make sure about
the previously obtained kinetic solubility results (to rule out potential
artifacts and to generate high quality solubility data using crystalline
material). This may be helpful to design formulation strategies for in vivo
studies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.